Yao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yao Wang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Hua Li
Department of Neurology, Guangdong Sanjiu Brain Hospital, Guangzhou, China
3 shared publications - Jing Guo
Department of Epilepsy Center Guangdong Sanjiu Brain Hospital Guangzhou China
2 shared publications Kai Peng
Epilepsy Center, Guangdong Sanjiu Brain Hospital, Guangzhou, Guangdong, China
2 shared publications- Anding Xu
Department of Neurology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
1 shared publication - Bing Yang
Department of Neurology, The First Affiliated Hospital of Jinan University, Clinical Neuroscience Institute, Jinan University, Guangzhou, China (L.L., B.Y., Y.W., C.Z., Z.L., F.L., S.Y., Y.L., Y.Y., X.L., L.H., A.X., H.Z.).
1 shared publication Chaoli Zhu
Department of Neurology, The First Affiliated Hospital of Jinan University, Clinical Neuroscience Institute, Jinan University, Guangzhou, China (L.L., B.Y., Y.W., C.Z., Z.L., F.L., S.Y., Y.L., Y.Y., X.L., L.H., A.X., H.Z.).
1 shared publication
Latest Publications
- Open Access
- 11 July 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1541-1555
Complete lesion resection and early surgical intervention are favorable factors for long‐term seizure freedom in drug‐resistant epileptic spasms
Objective: Epileptic spasms (ES) in children carry a high risk of neurodevelopmental delay, yet predictors of long‐term surgical outcome remain incompletely defined. This study aimed to evaluate seizure outcomes following epilepsy surgery and to identify independent prognostic factors for postoperative recurrence. Methods: This retrospective cohort study included 73 patients (47 males, 64%; median age at surgery: 37 months, IQR: 20–55.5) with drug‐resistant ES who underwent resective or ablative surgery at Guangdong Sanjiu Brain Hospital in China between January 2015 and September 2024, with regular follow‐up at least 12 months after epilepsy surgery. Independent predictors of recurrence were identified using multivariate Cox proportional hazards regression, and Kaplan–Meier analysis was performed to compare seizure‐free survival stratified by seizure duration (SD) and residual lesion status. Results: Seizure‐free rates were 75.3% at 1 year and 55.1% at last follow‐up. Mean follow‐up was 61.36 ± 26.10 months (range: 12–132). Among malformation of cortical development (MCD) subtypes, focal cortical dysplasia (FCD) type II demonstrated the highest 5‐year seizure‐free rate (100%), whereas mild MCD (m‐MCD) showed the lowest (33.3%; p = 0.039). On multivariate Cox analysis, residual lesion on postoperative MRI was the strongest independent predictor of recurrence (HR = 5.13; 95% CI: 2.28–11.51; p < 0.001), followed by SD exceeding 36 months (HR = 2.49; 95% CI: 1.17–5.29; p = 0.018). Kaplan–Meier analysis confirmed a twofold difference in 5‐year seizure‐free survival between patients with duration ≤36 versus >36 months (73% vs. 36%; log‐rank p = 0.00069), and significantly better seizure‐free survival in patients without residual lesions (log‐rank p < 0.0001). Significance: Complete lesion resection and early surgical intervention (SD ≤36 months) are independently associated with favorable long‐term seizure outcomes in children with drug‐resistant ES. Pathological subtype, particularly FCD type II, further refines prognostic stratification. These findings support prompt surgical referral and underscore the importance of achieving complete lesion removal to optimize postoperative seizure control. Plain Language Summary: Some children develop a severe form of epilepsy called epileptic spasms that cannot be controlled with medication. In this study of 73 children who had brain surgery for this condition, more than half remained seizure‐free after 5 years. Children who had surgery earlier—before seizures had continued for 3 years—and those in whom the entire abnormal brain tissue was removed did significantly better in the long run. These findings suggest that referring children for surgery sooner rather than later can meaningfully improve their chances of living seizure‐free.
- 11 July 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1541-1555
Open AccessComplete lesion resection and early surgical intervention are favorable factors for long‐term seizure freedom in drug‐resistant epileptic spasms
Objective: Epileptic spasms (ES) in children carry a high risk of neurodevelopmental delay, yet predictors of long‐term surgical outcome remain incompletely defined. This study aimed to evaluate seizure outcomes following epilepsy surgery and to identify independent prognostic factors for postoperative recurrence. Methods: This retrospective cohort study included 73 patients (47 males, 64%; median age at surgery: 37 months, IQR: 20–55.5) with drug‐resistant ES who underwent resective or ablative surgery at Guangdong Sanjiu Brain Hospital in China between January 2015 and September 2024, with regular follow‐up at least 12 months after epilepsy surgery. Independent predictors of recurrence were identified using multivariate Cox proportional hazards regression, and Kaplan–Meier analysis was performed to compare seizure‐free survival stratified by seizure duration (SD) and residual lesion status. Results: Seizure‐free rates were 75.3% at 1 year and 55.1% at last follow‐up. Mean follow‐up was 61.36 ± 26.10 months (range: 12–132). Among malformation of cortical development (MCD) subtypes, focal cortical dysplasia (FCD) type II demonstrated the highest 5‐year seizure‐free rate (100%), whereas mild MCD (m‐MCD) showed the lowest (33.3%; p = 0.039). On multivariate Cox analysis, residual lesion on postoperative MRI was the strongest independent predictor of recurrence (HR = 5.13; 95% CI: 2.28–11.51; p < 0.001), followed by SD exceeding 36 months (HR = 2.49; 95% CI: 1.17–5.29; p = 0.018). Kaplan–Meier analysis confirmed a twofold difference in 5‐year seizure‐free survival between patients with duration ≤36 versus >36 months (73% vs. 36%; log‐rank p = 0.00069), and significantly better seizure‐free survival in patients without residual lesions (log‐rank p < 0.0001). Significance: Complete lesion resection and early surgical intervention (SD ≤36 months) are independently associated with favorable long‐term seizure outcomes in children with drug‐resistant ES. Pathological subtype, particularly FCD type II, further refines prognostic stratification. These findings support prompt surgical referral and underscore the importance of achieving complete lesion removal to optimize postoperative seizure control. Plain Language Summary: Some children develop a severe form of epilepsy called epileptic spasms that cannot be controlled with medication. In this study of 73 children who had brain surgery for this condition, more than half remained seizure‐free after 5 years. Children who had surgery earlier—before seizures had continued for 3 years—and those in whom the entire abnormal brain tissue was removed did significantly better in the long run. These findings suggest that referring children for surgery sooner rather than later can meaningfully improve their chances of living seizure‐free.
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 1960-1970
Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial
BACKGROUND: Glucagon-like peptide-1 receptor agonists reduce major adverse cardiovascular events in type 2 diabetes. Although body mass index does not seem to modify these effects, whether insulin resistance influences treatment efficacy remains unclear. METHODS: This post hoc analysis of the LAMP trial (Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus; a multicenter, open-label, randomized controlled trial conducted at 27 hospitals in China between June 25, 2019, and December 27, 2023) included patients with minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes. Participants were randomized (1:1) to liraglutide plus standard therapy or standard therapy alone. IR was assessed using the homeostasis model assessment of IR, with a cutoff of 2.5 based on prior studies in Asian populations. Treatment-by-IR interactions were evaluated using Cox models. Absolute risk reduction was calculated as the difference in event rates between groups and was based on crude estimates. RESULTS: Among 636 enrolled patients, 510 were included in this analysis (mean age, 65 years; 64.7% male; follow-up, 3 months). A significant interaction between treatment and insulin resistance was observed for both stroke recurrence and composite vascular events ( P for interaction=0.02 for both). Among patients with homeostasis model assessment of IR ≥2.5, liraglutide reduced stroke recurrence (5.8% versus 18.1%; absolute risk reduction, 12.3% [95% CI, 5.6%–19.0%]; number needed to treat=8) and vascular events (5.8% versus 19.2%; absolute risk reduction, 13.4% [95% CI, 6.6%–20.2%]; number needed to treat=8). No significant benefit was observed in those with homeostasis model assessment of IR <2.5. CONCLUSIONS: IR may be an important determinant of the therapeutic efficacy of liraglutide in patients with acute minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes. IR-based stratification may help optimize the use of glucagon-like peptide-1 receptor agonists in secondary stroke prevention and guide personalized vascular risk management. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03948347.
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 1960-1970
Open AccessLiraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial
BACKGROUND: Glucagon-like peptide-1 receptor agonists reduce major adverse cardiovascular events in type 2 diabetes. Although body mass index does not seem to modify these effects, whether insulin resistance influences treatment efficacy remains unclear. METHODS: This post hoc analysis of the LAMP trial (Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus; a multicenter, open-label, randomized controlled trial conducted at 27 hospitals in China between June 25, 2019, and December 27, 2023) included patients with minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes. Participants were randomized (1:1) to liraglutide plus standard therapy or standard therapy alone. IR was assessed using the homeostasis model assessment of IR, with a cutoff of 2.5 based on prior studies in Asian populations. Treatment-by-IR interactions were evaluated using Cox models. Absolute risk reduction was calculated as the difference in event rates between groups and was based on crude estimates. RESULTS: Among 636 enrolled patients, 510 were included in this analysis (mean age, 65 years; 64.7% male; follow-up, 3 months). A significant interaction between treatment and insulin resistance was observed for both stroke recurrence and composite vascular events ( P for interaction=0.02 for both). Among patients with homeostasis model assessment of IR ≥2.5, liraglutide reduced stroke recurrence (5.8% versus 18.1%; absolute risk reduction, 12.3% [95% CI, 5.6%–19.0%]; number needed to treat=8) and vascular events (5.8% versus 19.2%; absolute risk reduction, 13.4% [95% CI, 6.6%–20.2%]; number needed to treat=8). No significant benefit was observed in those with homeostasis model assessment of IR <2.5. CONCLUSIONS: IR may be an important determinant of the therapeutic efficacy of liraglutide in patients with acute minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes. IR-based stratification may help optimize the use of glucagon-like peptide-1 receptor agonists in secondary stroke prevention and guide personalized vascular risk management. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03948347.
- Open Access
- 1 January 2026
- Published by Wiley in Genetics Research
- Vol. 2026 (1) , e8137770
Biological Context–Informed and Population‐Stratified Strategies Improve Genetic Diagnosis of CCDC22 ‐Related Disorder
Background: The CCDC22 gene is a key regulator of endosomal trafficking and NF‐κB signaling, and its dysfunction is implicated in a spectrum of X‐linked neurodevelopmental disorders, including Ritscher–Schinzel syndrome 2, intellectual disability, and epilepsy. Despite the identification of CCDC22 variants having increased, a comprehensive biological characterization, including its spatiotemporal expression and functional molecular networks, remains to be systematically delineated. Furthermore, the rarity of CCDC22 variants created a significant challenge in distinguishing their pathogenicity. This study aimed to explore the integration of biological context‐informed and clinical genetic analysis workflows and to perform an exploratory evaluation of prediction algorithms to better optimize the genetic diagnosis process for CCDC22 . Methods: Multilevel biological analysis was performed to evaluate the spatiotemporal expression patterns of CCDC22 across developmental stages. A protein–protein interaction network was constructed to identify key functional modules and pathway enrichments. Additionally, an expert‐classified dataset of CCDC22 missense variants was utilized to conduct an exploratory performance evaluation of twenty prediction algorithms, specifically assessing the effect of filtering out variants observed as population hemizygotes. Result: CCDC22 exhibits distinct spatiotemporal expression dynamics and chromatin accessibility patterns closely associated with neurodevelopmental processes. PPI and functional enrichment analyses highlighted its core involvement in endocytic recycling and vesicle transport. In the exploratory missense variant evaluation, meta‐predictors, notably ClinPred and MetaRNN, demonstrated the highest predictive potential within this limited cohort. After filtering out variants observed as hemizygotes in the gnomAD database, most of the algorithms’ performance improved in distinguishing the pathogenicity of variants and genetic diagnosis. ClinPred, M‐CAP, MetaRNN, and SIFT achieved the highest balanced accuracy (84.6%, 80.8%, 78.7%, and 76.1%, respectively). ClinPred, M‐CAP, and MetaRNN achieved the highest AUC value (> 0.9). Conclusion: This study delineates the spatiotemporal and functional molecular network of CCDC22 in neurodevelopment. A combination of population‐based strategy and prediction enhanced the performance of most algorithms. ClinPred and MetaRNN showed higher predictive potential. This study may provide insights into the evaluation of variants in CCDC22 ‐related diseases.
- 1 January 2026
- Published by Wiley in Genetics Research
- Vol. 2026 (1) , e8137770
Open AccessBiological Context–Informed and Population‐Stratified Strategies Improve Genetic Diagnosis of CCDC22 ‐Related Disorder
Background: The CCDC22 gene is a key regulator of endosomal trafficking and NF‐κB signaling, and its dysfunction is implicated in a spectrum of X‐linked neurodevelopmental disorders, including Ritscher–Schinzel syndrome 2, intellectual disability, and epilepsy. Despite the identification of CCDC22 variants having increased, a comprehensive biological characterization, including its spatiotemporal expression and functional molecular networks, remains to be systematically delineated. Furthermore, the rarity of CCDC22 variants created a significant challenge in distinguishing their pathogenicity. This study aimed to explore the integration of biological context‐informed and clinical genetic analysis workflows and to perform an exploratory evaluation of prediction algorithms to better optimize the genetic diagnosis process for CCDC22 . Methods: Multilevel biological analysis was performed to evaluate the spatiotemporal expression patterns of CCDC22 across developmental stages. A protein–protein interaction network was constructed to identify key functional modules and pathway enrichments. Additionally, an expert‐classified dataset of CCDC22 missense variants was utilized to conduct an exploratory performance evaluation of twenty prediction algorithms, specifically assessing the effect of filtering out variants observed as population hemizygotes. Result: CCDC22 exhibits distinct spatiotemporal expression dynamics and chromatin accessibility patterns closely associated with neurodevelopmental processes. PPI and functional enrichment analyses highlighted its core involvement in endocytic recycling and vesicle transport. In the exploratory missense variant evaluation, meta‐predictors, notably ClinPred and MetaRNN, demonstrated the highest predictive potential within this limited cohort. After filtering out variants observed as hemizygotes in the gnomAD database, most of the algorithms’ performance improved in distinguishing the pathogenicity of variants and genetic diagnosis. ClinPred, M‐CAP, MetaRNN, and SIFT achieved the highest balanced accuracy (84.6%, 80.8%, 78.7%, and 76.1%, respectively). ClinPred, M‐CAP, and MetaRNN achieved the highest AUC value (> 0.9). Conclusion: This study delineates the spatiotemporal and functional molecular network of CCDC22 in neurodevelopment. A combination of population‐based strategy and prediction enhanced the performance of most algorithms. ClinPred and MetaRNN showed higher predictive potential. This study may provide insights into the evaluation of variants in CCDC22 ‐related diseases.
- Open Access
- 23 December 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 134, 220-228
Gut microbiota signatures associated with ketogenic diet response in pediatric drug-resistant epilepsy
- 23 December 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 134, 220-228
Open AccessGut microbiota signatures associated with ketogenic diet response in pediatric drug-resistant epilepsy